Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vosaroxin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vosaroxin SCHEMBL15933161 | 1.00 | HTR3A (0.35) | HTR3AKMT2AALDH1A1PPARGMAPK10 | |
| Vosaroxin SCHEMBL674441 | 1.00 | HTR3A (0.35) | HTR3AKMT2AALDH1A1PPARGMAPK10 | |
| Vosaroxin SCHEMBL3207291 | 1.00 | HTR3A (0.35) | HTR3AKMT2AALDH1A1PPARGMAPK10 | |
| Vosaroxin SCHEMBL7824841 | 0.99 | HTR3A (0.35) | HTR3AKMT2AALDH1A1PPARGMAPK10 | |
| Vosaroxin SCHEMBL7824869 | 0.99 | HTR3A (0.35) | HTR3AKMT2AALDH1A1PPARGMAPK10 | |
| Vosaroxin SCHEMBL7824853 | 0.99 | HTR3A (0.35) | HTR3AKMT2AALDH1A1PPARGMAPK10 | |
| Vosaroxin SCHEMBL18694851 | 0.99 | HTR3A (0.35) | HTR3AKMT2AALDH1A1PPARGMAPK10 | |
| Vosaroxin SCHEMBL29914037 | 0.99 | HTR3A (0.35) | HTR3AKMT2AALDH1A1PPARGMAPK10 | |
| SCHEMBL15929815 | 0.94 | HTR3A (0.36) | HTR3AKMT2AALDH1A1PPARGMAPK10 | |
| SCHEMBL7836101 | 0.90 | ALDH1A1 (0.35) | HTR3AKMT2AALDH1A1PPARGMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382214-A1 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-Ý(3S,4S)-3METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL¨-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | Sunesis Pharmaceuticals, Inc. (US) | 2011-11-02 | — | — | EP | claimed |
| US-20110263524-A1 | SNS-595 AND METHODS OF USING THE SAME | SUNESIS PHARMACEUTICALS, INC. | 2011-10-27 | — | — | US | claimed |
| WO-2010078294-A1 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | SUNESIS PHARMACEUTICAL, INC. (US) | 2010-07-08 | — | — | WO | claimed |
| EP-2049109-A2 | COMBINED USE OF (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID AND CYTARABINE (ARA-C) FOR THE TREATMENT OF LEUKEMIA | Sunesis Pharmaceuticals, Inc. (US) | 2009-04-22 | — | — | EP | claimed |
| WO-2008016702-A2 | COMBINED USE OF (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | WO | claimed |
| EP-0787726-B1 | NOVEL COMPOUND, PROCESS FOR PRODUCING THE SAME, AND ANTITUMOR AGENT | DAINIPPON PHARMACEUTICAL CO (JP) | 2001-11-28 | — | — | EP | claimed |
| US-5817669-A | A COMPOUND CONTAINING 1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1998-10-06 | — | — | US | claimed |
| EP-0787726-A1 | NOVEL COMPOUND, PROCESS FOR PRODUCING THE SAME, AND ANTITUMOR AGENT | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1997-08-06 | — | — | EP | claimed |
| WO-2025033367-A1 | COMBINATION THERAPY FOR ANTITUMOR AGENT | 湧永製薬株式会社 | 2025-02-13 | — | — | WO | disclosed |
| EP-3604305-B1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMA CO LTD (JP) | 2024-08-28 | — | — | EP | disclosed |
| CN-110520422-B | Novel pyridonecarboxylic acid derivative or salt thereof | 涌永制药株式会社 | 2023-09-05 | — | — | CN | disclosed |
| US-11286255-B2 | Pyridone carboxylic acid derivative or salt thereof | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-29 | — | — | US | disclosed |
| US-20200062752-A1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2020-02-27 | — | — | US | disclosed |
| EP-3604305-A1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | Wakunaga Pharmaceutical Co., Ltd. (JP) | 2020-02-05 | — | — | EP | disclosed |
| WO-2008016702-A2 | COMBINED USE OF (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008016678-A2 | PHARMACEUTICAL DOSAGE FORMS FOR (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
| WO-2007146335-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | SUNESIS PHARMACEUTICALS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| EP-0787726-B1 | NOVEL COMPOUND, PROCESS FOR PRODUCING THE SAME, AND ANTITUMOR AGENT | DAINIPPON PHARMACEUTICAL CO (JP) | 2001-11-28 | — | — | EP | disclosed |
| US-5817669-A | A COMPOUND CONTAINING 1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1998-10-06 | — | — | US | disclosed |
| EP-0787726-A1 | NOVEL COMPOUND, PROCESS FOR PRODUCING THE SAME, AND ANTITUMOR AGENT | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1997-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062752-A1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | RAB10, HDAC10, NEK10 | HTR3A 3408/4885KMT2A 2507/4885ALDH1A1 207/4885 |
| US-11286255-B2 | Pyridone carboxylic acid derivative or salt thereof | RARA, RAB10, RABL6 | HTR3A 3858/4885KMT2A 2313/4885ALDH1A1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.